54 results about "Mrna level" patented technology

The invention discloses application of sauchinone in cardiac fibrosis, relates to the technical field of medicines, and particularly relates to application of pharmaceutically acceptable salt derivatives of sauchinone in preparation of medicines for treating and / or relieving cardiac fibrosis. The sauchinone disclosed by the invention inhibits proliferation and migration of fibroblasts induced by Ang II. The sauchinone has a potential anti-cardiac fibrosis effect. The sauchinone can reduce the area of cardiac fibrosis and down-regulate mRNA level and protein expression of fibrosis related indexes, so that the sauchinone shows a potential anti-fibrosis effect.

The invention provides a gene expression cassette for improving CsCE expression quantity and application. The gene expression cassette provided by the invention comprises a regulatory element and a target gene, the regulatory element comprises at least one of a coding sequence of dtRNA, a coding sequence of a signal peptide and a coding sequence of a fusion tag, and the target gene comprises a coding sequence of CsCE enzyme. Wherein the dtRNA contributes to keeping the structural stability when the CsCE enzyme is transcribed into mRNA, the signal peptide can promote the secretion of the CsCE enzyme, and the fusion tag can assist the correct folding of the CsCE enzyme, so that the expression of the CsCE enzyme can be synergistically regulated under the three-tube alignment of a DNA transcriptional mRNA layer, a protein secretion layer and a protein folding layer, the expression quantity of the CsCE enzyme can be effectively up-regulated, and the expression quantity of the CsCE enzyme can be effectively up-regulated. Therefore, the volume enzyme activity of the CsCE enzyme is improved, and the CsCE enzyme with higher volume enzyme activity can catalyze lactose to be converted into lactulose in the preparation of lactulose, so that the preparation yield of lactulose is improved.

The invention discloses a colorectal cancer diagnosis biomarker and application thereof. The biomarker is creatine kinase B (CKB). The invention proves that the expression of CKB in colorectal cancer tissues is obviously lower than that in paracancerous normal tissues, and the low expression of CKB is related to poor prognosis of patients. On the basis, the invention provides application of the CKB as the biomarker and a corresponding diagnostic kit. The kit can comprise an antibody or primer for detecting the CKB protein or mRNA level. The invention provides a new effective means for early diagnosis and prognosis of colorectal cancer.

This invention belongs to the field of biomedical technology and relates to a drug-loaded vesicle for promoting the healing of diabetic wounds. The drug-loaded vesicle has a core-shell structure. The core contains siRNA targeting ALKBH5 mRNA; the shell is a hybrid membrane of human umbilical vein endothelial cell membrane and milk-derived extracellular vesicle membrane, with its surface embedded with arginine-rich lipopeptides, and at least some arginine exposed outside the hybrid membrane. The core-shell structure effectively protects the siRNA from degradation and reduces off-target interference. The hybrid membrane shell has good biocompatibility, immunogenicity, and low cytotoxicity. The exposed arginine enhances tissue penetration and cellular uptake. In vitro and in vivo experiments have confirmed that this drug-loaded vesicle has good cellular uptake efficiency, effectively downregulates ALKBH5 expression, and restores mRNA levels. 6 A-modification increases the stability of C2orf69 mRNA, improves endothelial cell function, significantly promotes the healing of diabetic wounds, and has good biocompatibility and safety.

The application discloses application of a killer cell lectin-like receptor G1 (KLRG1) gene as a marker in preparation of a systemic lupus erythematosus (SLE) secondary hemophagocytic lymphohistiocytosis (HLH) detection preparation, and the preparation is used for detecting the expression level of the KLRG1 gene in a biological sample. Research finds that the expression level of the KLRG1 gene in SLE secondary HLH patients is significantly lower than that of healthy control groups and SLE patients, and has good diagnostic sensitivity and specificity. The application also discloses a preparation for detecting the expression level of the KLRG1 gene in a biological sample of a patient, the preparation contains a primer pair for detecting the mRNA level of the KLRG1 gene expression, or contains an antibody for detecting the protein level of the KLRG1 gene expression, and only needs to extract peripheral blood mononuclear cells (PBMC) after blood drawing to detect whether SLE patients are secondary to HLH, and the preparation is simple, rapid, and accurate in result.

The invention discloses an application of PINK1 in regulation and control of ER positive breast cancer tamoxifen drug resistance. The invention relates to application of PINK1 as a biomarker in evaluating the tamoxifen resistance of ER positive breast cancer cells. The drug resistance is evaluated by detecting the expression level of PINK1 in a sample and combining mitochondrial autophagy activity. The expression level of the PINK1 comprises an mRNA level and / or a protein level. According to the invention, the drug resistance formation process is systematically analyzed from the perspective of quality control of an organelle of mitochondrial autophagy, and through public database analysis and experimental verification, the overall up-regulation of the mitochondrial autophagy pathway in drug-resistant cells is clearly revealed, and the drug-resistant phenotype is promoted by maintaining the mitochondrial steady state, thereby opening up a new direction for understanding the drug-resistant mechanism.

The application discloses application of miRNA-23c as a gene targeting METTL3 in preparation of a medicine for preventing or treating bladder cancer. The application discloses a miRNA for inhibiting growth of bladder cancer, the miRNA-23c is complementary to the 3'-UTR of the mRNA of the METTL3 gene, can inhibit translation of the mRNA of a target gene or directly degrade the mRNA of the target gene. Fluorescent luciferase reporter gene analysis in an EJ cell line verifies that the METTL3 is a target gene of the miRNA-23c, then overexpression of the miRNA-23c in the EJ cell line finds that the miRNA-23c significantly down-regulates the mRNA level of the METTL3. The application first reports that the METTL3 can be a target gene of the miRNA-23c. The application provides certain application value in the aspect of using the miRNA as a drug target point for bladder cancer treatment.

The invention discloses siRNA (small interfering Ribonucleic Acid) of targeted bone morphogenetic protein 2, modified siRNA and application of the siRNA. According to the invention, siRNA drug design is carried out by taking the BMP2 gene as a target gene to obtain a series of siRNAs, siRNAs capable of effectively silencing the mRNA expression level of the BMP2 gene are screened from the siRNAs, and part of siRNA sequences can even silence the mRNA level of the BMP2 gene to about 25%. The siRNA sequence is further modified, wherein phosphorylation or phosphorylation analogue modification, skeleton modification, sugar ring modification and basic group modification are carried out on the 5'terminal of the sequence, or cholesterol molecule modification is carried out on the end group of the siRNA. The siRNA sequence is further subjected to cholesterol modification to obtain a human-mouse homologous sequence of the targeted BMP2 gene, and the in-vivo silencing activity of the BMP2 target spot is further researched in a mouse experimental model subsequently.

This invention belongs to the field of cell detection technology, specifically involving the application of NR4A1 as an early biomarker for gamma-ray radiation. This invention discovers that in the early stage (2 hours) after gamma-ray radiation, the protein and mRNA levels of NR4A1 are significantly increased, exhibiting a radiation dose-dependent effect. NR4A1 can serve as a 2-hour biomarker for gamma-ray irradiated HeLa cells, allowing for the screening of cells irradiated for 2 hours, differentiating the duration of gamma-ray irradiation, and achieving early diagnosis of cellular gamma-ray radiation.

The invention belongs to the technical field of biological medicines, and discloses application of a CCT6A inhibitor in preparation of a medicine for treating colorectal cancer. CCT6A is determined to be a key cancer promoting gene of colorectal cancer for the first time, the CCT6A is remarkably and highly expressed in colorectal cancer tissues and cell lines, and high expression indicates poor prognosis of patients, so that a brand-new specific target is provided for targeted therapy of colorectal cancer. The invention discloses the cancer promoting effect of the compound in colorectal cancer and the association with 5FU drug resistance for the first time, enriches the development of colorectal cancer and the molecular mechanism research of chemotherapy drug resistance, and provides a new theoretical basis and research direction for the fundamental research in the field. Experiments prove that the inhibitor can significantly reduce the mRNA level of CCT6A in colorectal cancer cells so as to strongly inhibit tumor cell proliferation and increase the sensitivity of the colorectal cancer cells to 5-FU, and a novel therapeutic drug with high specificity and high curative effect is provided for treatment of colorectal cancer.

Provided is a compact RNA-editing platform engineered from IscB, which has comparable or higher activity than Cas13, but with less or no cytotoxicity. IscB, has intrinsic affinity for complementary single-stranded (ss)DNA and RNA. This activity becomes dominant when its dsDNA binding activity is switched off, through the deletion or mutation of its Target Adjacent Motif domain, resulting in a modified IscB. The resulting R-IscB is comparable or better than Cas13, can efficiently alter splicing outcomes in human cells, and can mediate trans-splicing to correct mutations at the mRNA level. R-IscB also drives efficient A-to-I editing on mRNA when fused to ADAR2 and mediates cleavage-based mRNA knockdown upon HNH engineering. The same approach converts some Cas9s to RNA-targeting tools.

The present application relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of target immune drug for primary liver cancer and application thereof, wherein the combined marker is folate receptor gamma gene FOLR3, stratified protein gene SFN and coiled-coil domain containing 9 gene CCDC9 derived from peripheral blood leukocyte mRNA.The present application performs combined detection based on multiple peripheral blood leukocyte markers, and compared with a single molecular marker, can reduce errors caused by individual expression difference of a single index to some extent, so that the detection result is more accurate.The curative effect prediction model constructed based on detection of peripheral blood leukocyte mRNA level change can specifically recognize and detect in the early stage of tumor formation, has high sensitivity and high specificity, provides an important means for reasonable use of target immune drug for liver cancer patients sensitive or resistant to target immune drug, and has great significance for effective treatment of liver cancer in China.

The invention discloses application of a deubiquitinating enzyme STAMBPL1 as a pancreatic cancer diagnostic kit and in targeted drug development. According to the research, by mining a TCGA-PAAD public data set of a TCGA database, the transcriptome expression level of STAMBPL1 in pancreatic cancer tissue is found to be remarkably higher than that in normal tissue. The research also finds that the proliferation and migration of the human pancreatic cancer cell line PANC-1 can be inhibited in vitro by knocking down the STAMBPL1 through the small interfering RNA, and the mRNA level expression quantity of tumor proliferation and cell cycle related genes is reduced. According to the expression difference of the STAMBPL1 in pancreatic cancer derived from a patient and normal tissue and the experimental results of cell phenotype and gene transcription level expression detection after knockdown, the STAMBPL1 can be possibly used as a potential biomarker of pancreatic cancer and a potential target of a pancreatic cancer diagnostic kit.

The application discloses a sophora japonica composition for refractory enteritis and a preparation method and application thereof. The sophora japonica composition for refractory enteritis comprises the following components: sophora japonica, dried orange peel, panax notoginseng, momordica grosvenori and lycoris radiata, and the sophora japonica composition for refractory enteritis is obtained by fermenting plant lactobacillus. The sophora japonica composition for refractory enteritis of the application can obviously increase the amount of duhrlactobacillus, lactobacillus and bifidobacterium and reduce the amount of clostridium in the process of treating inflammatory enteritis; can effectively inhibit the inflammation of colitis, and the mRNA level of inflammatory cytokines TNF-alpha, IL-22, IL-1beta and IL-6 is obviously reduced. The sophora japonica composition can obviously inhibit intestinal inflammation, promote the metabolism of intestinal short-chain fatty acids, increase the thickness of intestinal mucosa, and has obvious curative effects on intestinal microecological homeostasis of inflammatory bowel disease, intestinal inflammation and protection of intestinal mucosa.

The invention discloses siRNA for inhibiting ASGR1 expression and application of the siRNA, and belongs to the technical field of molecular biology. The preparation method comprises the following steps: firstly, designing siRNA according to an ASGR1 sequence, and carrying out transient transfection on the designed siRNA; according to the present invention, RT-qPCR (reverse transcription-quantitative polymerase chain reaction) and Western blotting are adopted to verify the ASGR1 expression inhibition effect; experiments prove that the siRNA molecule provided by the invention can be used for effectively inhibiting the expression of ASGR1; the protein is further delivered into a body through a carrier, the mRNA level is obviously reduced, protein expression is obviously inhibited, and a new method is provided for research and development of drugs for treating fatty liver, hyperlipidemia and high cholesterol.

The present invention relates to a disease-specific biomarker for early prediction and diagnosis of preeclampsia and use thereof, and a composition for prediction or diagnosis of preeclampsia according to an aspect or a method of providing information for prediction or diagnosis thereof, can simply and effectively predict or diagnose the disease by measuring and comparing the mRNA level of a disease-specific protein or a gene encoding the protein changed in a patient.

The invention discloses application of isolorydine hydrochloride in preparation of antiviral drugs, and belongs to the technical field of biological medicines. The invention discloses the antiviral effect, especially the PEDV (porcine epidemic diarrhea virus) resisting effect of the isolorydine hydrochloride for the first time. On Vero cells infected by PEDV (porcine epidemic diarrhea virus), 100 [mu] M of isolorydine hydrochloride has no cytotoxicity, and the median inhibitory concentration IC50 of the isolorydine hydrochloride is 6.78 [mu] M. In a host cell IPEC-LD, the isolorydine hydrochloride has no cytotoxicity when the isolorydine hydrochloride is 100 [mu] M and shows slight toxicity when the isolorydine hydrochloride is 200 [mu] M, 5 [mu] M of isolorydine hydrochloride can significantly reduce the mRNA level of PEDV N, and 10 [mu] M of isolorydine hydrochloride can significantly inhibit expression of PEDV N protein. The compound is used for preparing the medicine for resisting the porcine epidemic diarrhea virus, and has the advantages of reliable curative effect, no toxic or side effect, abundant resources, low price and the like.

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.

The present invention relates to a biomarker for diagnosing neuromyelitis optica and its use. Specifically, the present invention relates to a biomarker composition for diagnosing neuromyelitis optica comprising one or more genes selected from the group consisting of Plac8 (placenta-specific 8), Klra2 (killer cell lectin-like receptor, subfamily A, member 2) and Mcoln2 (mucolipin 2) or a protein expressed from said genes; a composition for diagnosing neuromyelitis optica comprising a substance for measuring the mRNA level of said genes or the protein level thereof; a diagnostic kit for neuromyelitis optica comprising said composition; and a method for providing information for predicting and diagnosing neuromyelitis optica.

The invention discloses application of a serine protease inhibitor in preparation of antiviral drugs, and belongs to the technical field of biological medicines. The two serine protease inhibitors, namely the camostat mesylate and the nafamostat mesylate, can almost completely inhibit cytopathy under the action of the concentration of 2 mu M, have a remarkable effect of inhibiting virus replication and proliferation in various PEDV susceptible cells, reduce the mRNA (messenger ribonucleic acid) level of PEDV N (porcine epidemic diarrhea virus N) and inhibit the expression of PEDV N protein. The compound is used for preparing the medicine for resisting the porcine epidemic diarrhea virus, and has the advantages of reliable curative effect, no toxic or side effect, abundant resources, low price and the like.

The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of SEC24D in preparation of medicines for treating atherosclerosis. The amino acid sequence of the SEC24D is as shown in SEQ ID NO.1. The medicine is a preparation which takes the SEC24D as a target spot and can inhibit the expression of the SEC24D. Clinical data and basic experiments prove that the SEC24D plays an important role in inflammation, the mRNA level of whole blood cells of the SEC24D is increased to reflect the activation of the inflammation, and we find that the mRNA level and protein level of the SEC24D are increased in the polarization process of M1 macrophages, the expression of the macrophages SEC24D is reduced, the functions of the M1 macrophages can be inhibited, and inflammatory mediators can be reduced.

Type-C endogenous retroviruses (ERVs) embedded in Chinese hamster ovary (CHO) cells were altered to modify the release of retroviral and / or retroviral-like particles in the culture supernatant. Although evidence for the infectivity of these particles is missing. their presence has raised safety concerns. 173 type-C ERV sequences that clustered into functionally conserved groups were identified. Transcripts from one type-C ERV group were identified to be full-length with intact open reading frames, and to have corresponding viral RNA genomes that were loaded into retroviral-like particles. Also, sequence analysis of the genomic RNA from viral particles indicated that they may result from few expressed ERV sequences. Disclosed herein is the disruption / alteration of the gag gene of the expressed ERV group using CRISPR-Cas9 genome editing. Comparison of CRISPR-derived mutations at the DNA and mRNA level led to the identification of a single ERV locus responsible for the release of viral RNA-loaded particles from CHO cells. Clones bearing a Gag loss-of-function mutation in this particular ERV locus showed a reduction of viral RNA-containing particles in the cell supernatant by over 250-fold. Notably, ERV mutagenesis did not compromise cell growth, cell size or recombinant protein production. Provided herein is a new strategy and cells, in particular engineered CHO cells, to mitigate potential contaminations from CHO endogenous retroviruses during biopharmaceutical manufacturing.

The application of PQLC2 gene in the preparation of drugs for treating liver cancer and diagnostic kits belongs to the field of biological medicine. The present application finds that the expression of PQLC2 in liver cancer tissue is obviously higher than that in normal tissue through statistical analysis of the expression of PQLC2 in liver cancer tissue and normal liver tissue of hepatocellular carcinoma patients in TCGA database. And the expression vector interfering with PQLC2 gene is used to prove that the expression level of PQLC2 gene can inhibit the proliferation and migration of liver cancer cells through in vitro cell function experiment. The real-time fluorescent quantitative PCR experiment shows that the mRNA level of genes CCND1, MMP14, p21 and BIM related to the regulation of cell cycle and apoptosis is significantly changed after the expression of PQLC2 gene is interfered, which confirms that PQLC2 can promote the occurrence and development of liver cancer from the molecular level of gene, and indicates that PQLC2 can be used as a target for clinical treatment of liver cancer.

The application discloses application of a killer cell lectin-like receptor C3 (KLRC3) gene as a marker in preparation of a systemic lupus erythematosus (SLE) secondary hemophagocytic lymphohistiocytosis (HLH) detection preparation, and the preparation is used for detecting the expression level of the KLRC3 gene in a biological sample. Research finds that the KLRC3 gene expression level in SLE secondary HLH patients is significantly lower than that in a healthy control group and SLE patients, and has good diagnostic sensitivity and specificity. The application also discloses a preparation for detecting the KLRC3 gene expression level in a biological sample of a patient, the preparation contains a primer pair for detecting the mRNA level of the KLRC3 gene expression, or contains an antibody for detecting the protein level of the KLRC3 gene expression, and only needs to extract peripheral blood mononuclear cells (PBMC) from blood to detect whether SLE patients are secondary to HLH, and the preparation is simple, rapid and accurate in result.

The application belongs to the technical field of biomarker diagnostic products, and relates to application of UBALD2 as a marker in a hepatocellular carcinoma diagnostic product, and application of a substance for detecting UBALD2 expression level in an in-vitro detection reagent, a detection kit and / or an in-vitro prognosis evaluation product. The application proves that UBALD2 is highly expressed in hepatocellular carcinoma tissues from two aspects of protein level and mRNA level, and indicates that UBALD2 can be used as one of molecular indexes reflecting the occurrence and development state of hepatocellular carcinoma. The application proposes that high expression of UBALD2 is related to poor overall survival of patients, and is related to a later T stage, and indicates that the substance for detecting UBALD2 can be used for prognosis risk evaluation, prognosis stratification and clinical auxiliary judgment products of hepatocellular carcinoma patients, and provides a reference basis for individualized management of patients.

The application belongs to the field of medicine and biotechnology, and particularly relates to application of a substance for reducing KDM1A content or activity in preparation of a product for treating non-alcoholic fatty liver disease and related diseases. In the application, the substance for reducing KDM1A content or activity in preparation of the product for treating non-alcoholic fatty liver disease and related diseases is at least one selected from a KDM1A protein content or activity reducing inhibitor, a KDM1A mRNA content or activity reducing inhibitor, and a CRISPR-Cas9 gene knockout system targeting a KDM1A gene. The application finds a new use of the KDM1A gene, and inhibiting expression of KDM1A protein or inhibiting KDM1A protein or inhibiting mRNA level of KDM1A in cells or tissues can play a role in protecting the liver and inhibiting non-alcoholic fatty liver disease.

The invention discloses a method for auxiliary assessment of early risk of Alzheimer's disease based on EFEMP1 detection. The method is an in-vitro non-diagnostic analysis method, and comprises the following steps: detecting the biomarker level of EFEMP1 in a biological sample of a subject, and obtaining information for evaluating the AD early risk of the subject based on a detection result. The biomarker comprises an EFEMP1 genotype, an EFEMP1 mRNA (messenger Ribonucleic Acid) expression level or an EFEMP1 protein concentration. When the risk assessment is realized by quantitatively detecting the concentration of the EFEMP1 protein in the plasma, an immunodetection kit containing a capture antibody and a detection antibody aiming at different epitopes of the EFEMP1 protein can be specifically adopted. Objective information for risk judgment is obtained by detecting the protein concentration, genotype or mRNA level of EFEMP1 in a biological sample of a subject, early-stage and non-invasive monitoring of an AD upstream pathological mechanism is achieved, and a new strategy is provided for early warning of diseases.

The present invention relates to several biomarkers, including IL-1RA, IFN-γ and GM-CSF, whose expressions at the mRNA level and at the protein level, correlate with chronic pathologies, such as Lyme disease, in particular the late chronic form of Lyme disease. More specifically, the invention provides methods and kits for the diagnosis of such chronic pathologies and for the assessment of a patient's response to a treatment, as well as methods and therapeutic agents for the treatment of such chronic pathologies.

This invention discloses the application of NADK inhibitors in the preparation of drugs for treating liver cancer, such as siRNA targeting NADK. This invention demonstrates that NADK inhibitors can be used to treat liver cancer, and the siRNA provided by this invention exhibits stronger cytotoxicity against HepG2 cells compared to previously disclosed NADK target sequences, effectively inhibiting the proliferation of liver cancer cells both in vitro and in vivo, achieving a tumor-suppressive effect. Furthermore, the siRNA designed in this invention can simultaneously knock down the mRNA levels of both human and mouse NADK genes, facilitating scientific research and the development of tumor drugs.

The invention relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of a primary hepatocellular carcinoma target-free drug and application of the combined marker, and the combined marker is a folate receptor gamma gene FOLR3 derived from peripheral blood leucocyte mRNA, a layered protein gene SFN and a coiled-coil domain protein 9 gene CCDC9. According to the invention, combined detection is carried out based on a plurality of peripheral blood leucocyte markers, and compared with a single molecular marker, errors caused by individual expression difference of a single index can be reduced to a certain extent, so that the detection result is more accurate. The curative effect prediction model constructed based on detection of peripheral blood leucocyte mRNA level change can perform specific recognition detection in the initial stage of tumor formation, has high sensitivity and high specificity, and provides an important means for reasonable medication of hepatocellular carcinoma patients sensitive or resistant to target-free drugs. The important significance is realized on the effective treatment of the hepatocellular carcinoma in China.